摘要
目的确认并量化螺内酯与上消化道出血和溃疡之间的联系。设计人群为基础的病例对照研究。背景环境荷兰的初级保健信息数据库。参加者数据库中从1996年1月1日至2003年9月30日,所有年龄大于等于18岁的人。排除曾有酒精中毒或消化道肿瘤病史的患者。每个胃十二指肠溃疡或上消化道出血的病例配比十个对照,按年龄(出生年)、性别和索引日期进行匹配。主要结果评价使用条件 Logistic 回归分析,根据潜在的混杂因子对上消化道事件(出血或穿孔)的发生做出校正。结果在源人群中的306645位患者中,确认523个胃十二指肠溃疡或上消化道出血病例,与5230个对照进行配比。正在应用螺内酯治疗与消化道事件风险胜增加2.7倍相关联(95%可信区间1.2～6.0)。结论胃十二指肠溃疡或上消化道出血发生风险在使用螺内酯的患者中明显增加。
Objective To confirm and quantify any association between spironolactone and upper gastrointestinal bleeding and ulcers. Design Population based case-control study. Setting A primary care information database in the Netherlands. Participants All people on the database who were aged 18 or more between 1 January 1996 and 30 September 2003. Patients with a history of alcoholism or gastrointestinal cancer were excluded. Ten controls were matched to each case of gastroduodenal ulcer or upper gastrointestinal bleeding by age （ year of birth ） , sex, and index date. Main outcome measures The occurrence of an upper gastrointestinal event （ bleeding or ulcers） , adjusted for potential confounders with conditional logistic regression analysis. Results Within the source population of 306 645 patients, 523 eases of gastric or duodenal ulcer or upper gastrointestinal bleeding were identified and matched to 5230 controls. Current use of spironolaetone was associated with a 2.7-fold （95% confidence interval 1.2 to 6.0） increased risk of a gastrointestinal event. Conclusion The risk of gastroduodenal ulcers or upper gastrointestinal bleeding is significantly increased in patients using spironolaetone.
出处
《英国医学杂志中文版》
2007年第1期20-24,共5页
The BMJ Chinese Edition
基金
None
